Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 5/2007

Open Access 01-10-2007 | Research article

A critical evaluation of loss of heterozygosity detected in tumor tissues, blood serum and bone marrow plasma from patients with breast cancer

Authors: Heidi Schwarzenbach, Volkmar Müller, Cord Beeger, Miriam Gottberg, Nicole Stahmann, Klaus Pantel

Published in: Breast Cancer Research | Issue 5/2007

Login to get access

Abstract

Introduction

The aim of the study was to perform a comparative analysis of LOH (loss of heterozygosity) in primary tumors as well as peripheral blood and bone marrow (BM) of patients with breast cancer (BCa).

Methods

Performing PCR-based fluorescence microsatellite analysis and using a panel of seven polymorphic microsatellite markers, we compared the profiles of LOH in primary tumors, peripheral blood and BM plasma from patients with primary BCa (n = 40, stage M0) as well as tumor tissues and blood serum from metastatic BCa patients (n = 48, stage M1). During the course of systemic treatment blood samplings from 12 M0 and 16 M1 patients were at least once repeated.

Results

The overall incidences of LOH in tumor tissues, blood and BM samples were 27.5%, 9.0% and 5.0%, respectively. The marker D3S1255 was the only one in the panel that showed similar frequencies of LOH ranging from 19.0 to 24.5% in tumor, blood and BM samples. Both M0 blood serum and BM plasma samples displayed the same rate of 19.0%, whereas tumor and M1 serum showed a rate of 24.5% and 24.0%, respectively, at this locus. This marker also showed the highest frequency of LOH in serum and BM samples, whereas in tumor samples LOHs at the markers D13S218 (38%) and D17S855 (36%) were more frequent. Statistical analysis of the tumor samples showed that occurrence of LOH at the markers D3S1255 (P < 0.04), D9S171 (P < 0.05) and D17S855 (P < 0.03) correlated with undifferentiated nuclear grade. Additionally, significant associations of the number of LOH recorded at D17S250 with estrogen receptor (P < 0.02), progesterone receptor (P < 0.03) expression and high proliferation score (Ki-67 expression, P = 0.009) were observed. In blood serum samples a relationship between positive lymph node status and LOH at the marker D3S1255 was revealed (M0 stage, P = 0.05; M0+M1 stage, P = 0.004).

Conclusion

Our study demonstrates heterogeneous profiles and low rates of LOH, particularly on free DNA in BM and blood samples. However, the significant associations of LOH with some risk factors and the demonstrated possibility of monitoring free DNA in patients undergoing systemic therapy suggest that LOH analysis may be developed into a useful diagnostic tool.
Appendix
Available only for authorised users
Literature
1.
Colozza M, Cardoso F, Sotiriou C, Larsimont D, Piccart MJ: Bringing molecular prognosis and prediction to the clinic. Clin Breast Cancer. 2005, 6: 61-76.CrossRefPubMed
2.
Pantel K, Brakenhoff RH: Dissecting the metastatic cascade. Nat Rev Cancer. 2004, 4: 448-456. 10.1038/nrc1370.CrossRefPubMed
3.
Pantel K, Alix-Panabières C: The clinical significance of circulating tumor cells. Nat Clin Pract Oncol. 2007, 4: 62-63. 10.1038/ncponc0737.CrossRefPubMed
4.
Beckmann MW, Niederacher D, Schnurch HG, Gusterson BA, Bender HG: Multistep carcinogenesis of breast cancer and tumour heterogeneity. J Mol Med. 1997, 75: 429-439. 10.1007/s001090050128.CrossRefPubMed
5.
Ingvarsson S: Genetics of breast cancer. Drugs Today (Barc). 2004, 40: 991-1002. 10.1358/dot.2004.40.12.872574.CrossRef
6.
Yang X, Tahin Q, Hu YF, Russo IH, Balsara BR, Mihaila D, Slater C, Barrett JC, Russo J: Functional roles of chromosomes 11 and 17 in the transformation of human breast epithelial cells in vitro. Int J Oncol. 1999, 15: 629-638.PubMed
7.
Seitz S, Frege R, Jacobsen A, Weimer J, Arnold W, von Haefen C, Niederacher D, Schmutzler R, Arnold N, Scherneck S: A network of clinically and functionally relevant genes is involved in the reversion of the tumorigenic phenotype of MDA-MB-231 breast cancer cells after transfer of human chromosome 8. Oncogene. 2005, 24: 869-879. 10.1038/sj.onc.1208260.CrossRefPubMed
8.
Nessling M, Richter K, Schwaenen C, Roerig P, Wrobel G, Wessendorf S, Fritz B, Bentz M, Sinn HP, Radlwimmer B, et al: Candidate genes in breast cancer revealed by microarray-based comparative genomic hybridization of archived tissue. Cancer Res. 2005, 65: 439-447.PubMed
9.
Dahiya RDG: Molecular prognostic markers in breast cancer. Breast Cancer Res Treat. 1998, 52: 185-200. 10.1023/A:1006101729631.CrossRefPubMed
10.
O'Connell P: Genetic and cytogenetic analyses of breast cancer yield different perspectives of a complex disease. Breast Cancer Res Treat. 2003, 78: 347-357. 10.1023/A:1023037925950.CrossRefPubMed
11.
Stratton MR, Collins N, Lakhani SR, Sloane JP: Loss of heterozygosity in ductal carcinoma in situ of the breast. J Pathol. 1995, 175: 195-201. 10.1002/path.1711750207.CrossRefPubMed
12.
Dumitrescu RG, Cotarla I: Understanding breast cancer risk – where do we stand in 2005?. J Cell Mol Med. 2005, 9: 208-221. 10.1111/j.1582-4934.2005.tb00350.x.CrossRefPubMed
13.
Yoshida K, Miki Y: Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage. Cancer Sci. 2004, 95: 866-871. 10.1111/j.1349-7006.2004.tb02195.x.CrossRefPubMed
14.
Sourvinos G, Kiaris H, Tsikkinis A, Vassilaros S, Spandidos DA: Microsatellite instability and loss of heterozygosity in primary breast tumours. Tumour Biol. 1997, 18: 157-166.CrossRefPubMed
15.
Driouch K, Dorion-Bonnet F, Briffod M, Champeme MH, Longy M, Lidereau R: Loss of heterozygosity on chromosome arm 16q in breast cancer metastases. Genes Chromosomes Cancer. 1997, 19: 185-191. 10.1002/(SICI)1098-2264(199707)19:3<185::AID-GCC8>3.0.CO;2-U.CrossRefPubMed
16.
Stroun M, Maurice P, Vasioukhin V, Lyautey J, Lederrey C, Lefort F, Rossier A, Chen XQ, Anker P: The origin and mechanism of circulating DNA. Ann NY Acad Sci. 2000, 906: 161-168.CrossRefPubMed
17.
Stroun M, Lyautey J, Lederrey C, Olson-Sand A, Anker P: About the possible origin and mechanism of circulating DNA apoptosis and active DNA release. Clin Chim Acta. 2001, 313: 139-142. 10.1016/S0009-8981(01)00665-9.CrossRefPubMed
18.
Jahr S, Hentze H, Englisch S, Hardt D, Fackelmayer FO, Hesch RD, Knippers R: DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res. 2001, 61: 1659-1665.PubMed
19.
Chun FKH, Müller I, Lange I, Friedrich M, Erbersdobler A, Karakiewicz PI, Graefen M, Pantel K, Huland H, Schwarzenbach H: Circulating tumour-associated plasma DNA represents an independent and informative predictor of prostate cancer. BJU Int. 2006, 98: 544-548. 10.1111/j.1464-410X.2006.06352.x.CrossRefPubMed
20.
Schwarzenbach H, Müller V, Stahmann N, Pantel K: Detection and characterization of circulating microsatellite-DNA in blood of patients with breast cancer. Ann NY Acad Sci. 2004, 1022: 25-32. 10.1196/annals.1318.005.CrossRefPubMed
21.
Müller I, Urban K, Pantel K, Schwarzenbach H: Comparison of genetic alterations detected in circulating Microsatellite-DNA in blood plasma samples of patients with prostate cancer and benign prostatic hyperplasia. Ann NY Acad Sci. 2006, 1075: 222-229. 10.1196/annals.1368.030.CrossRefPubMed
22.
Schwarzenbach H, Chun FKH, Lange I, Carpenter S, Gottberg M, Erbersdobler A, Friedrich MG, Huland H, Pantel K: Detection of Tumor-specific DNA in blood and bone marrow plasma from Patients with Prostate Cancer. Int J Cancer. 2007, 120: 1465-1471. 10.1002/ijc.22470.CrossRefPubMed
23.
Silva JM, Silva J, Sanchez A, Garcia JM, Dominguez G, Provencio M, Sanfrutos L, Jareno E, Colas A, Espana P, Bonilla F: Tumor DNA in plasma at diagnosis of breast cancer patients is a valuable predictor of disease-free survival. Clin Cancer Res. 2002, 8: 3761-3766.PubMed
24.
Taback B, Fujiwara Y, Wang HJ, Foshag LJ, Morton DL, Hoon DS: Prognostic significance of circulating microsatellite markers in the plasma of melanoma patients. Cancer Res. 2001, 61: 5723-5726.PubMed
25.
Chen XQ, Stroun M, Magnenat JL, Nicod LP, Kurt AM, Lyautey J, Lederrey C, Anker P: Microsatellite alterations in plasma DNA of small cell lung cancer patients. Nat Med. 1996, 2: 1033-1035. 10.1038/nm0996-1033.CrossRefPubMed
26.
Anker P, Lefort F, Vasioukhin V, Lyautey J, Lederrey C, Chen XQ, Stroun M, Mulcahy HE, Farthing MJ: K-ras mutations are found in DNA extracted from the plasma of patients with colorectal cancer. Gastroenterology. 1997, 112: 1114-1120. 10.1016/S0016-5085(97)70121-5.CrossRefPubMed
27.
Nawroz H, Koch W, Anker P, Stroun M, Sidransky D: Microsatellite alterations in serum DNA of head and neck cancer patients. Nat Med. 1996, 2: 1035-1037. 10.1038/nm0996-1035.CrossRefPubMed
28.
Remmele W, Stegner HE: Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe. 1987, 8: 138-140.PubMed
29.
Wang Q, Larson PS, Schlechter BL, Zahid N, Finnemore E, de las Morenas A, Blanchard RA, Rosenberg CL: Loss of heterozygosity in serial plasma DNA samples during follow-up of women with breast cancer. Int J Cancer. 2003, 106: 923-929. 10.1002/ijc.11333.CrossRefPubMed
30.
Coulet F, Blons H, Cabelguenne A, Lecomte T, Laccourreye O, Brasnu D, Beaune P, Zucman J, Laurent-Puig P: Detection of plasma tumor DNA in head and neck squamous cell carcinoma by microsatellite typing and p53 mutation analysis. Cancer Res. 2000, 60: 707-711.PubMed
31.
Hibi K, Robinson CR, Booker S, Wu L, Hamilton SR, Sidransky D, Jen J: Molecular detection of genetic alterations in the serum of colorectal cancer patients. Cancer Res. 1998, 58: 1405-1407.PubMed
32.
Kopreski MS, Benko FA, Kwee C, Leitzel KE, Eskander E, Lipton A, Gocke CD: Detection of mutant K-ras DNA in plasma or serum of patients with colorectal cancer. Br J Cancer. 1997, 76: 1293-1299.CrossRefPubMedPubMedCentral
33.
Müller V, Stahmann N, Riethdorf S, Rau T, Zabel T, Goetz A, Jänicke F, Pantel K: Circulating Tumor Cells in Breast Cancer: Correlation to Bone Marrow Micrometastases, Heterogeneous Response to Systemic Therapy and Low Proliferative Activity. Clin Cancer Res. 2005, 11: 3678-3685. 10.1158/1078-0432.CCR-04-2469.CrossRefPubMed
34.
Janni W, Rack B, Schindlbeck C, Strobl B, Rjosk D, Braun S, Sommer H, Pantel K, Gerber B, Friese K: The persistence of isolated tumor cells in bone marrow from patients with breast carcinoma predicts an increased risk for recurrence. Cancer. 2005, 103: 884-891. 10.1002/cncr.20834.CrossRefPubMed
35.
Silva JM, Garcia JM, Dominguez G, Silva J, Miralles C, Cantos B, Coca S, Provencio M, Espana P, Bonilla F: Persistence of tumor DNA in plasma of breast cancer patients after mastectomy. Ann Surg Oncol. 2002, 9: 71-76. 10.1245/aso.2002.9.1.71.CrossRefPubMed
36.
Lichy JH, Dalbegue F, Zavar M, Washington C, Tsai MM, Sheng ZM, Taubenberger JK: Genetic heterogeneity in ductal carcinoma of the breast. Lab Invest. 2000, 80: 291-301.CrossRefPubMed
37.
Hannelius U, Gherman L, Mäkelä VV, Lindstedt A, Zucchelli M, Lagerberg C, Tybring G, Kere J, Lindgren CM: Large-scale zygosity testing using single nucleotide polymorphisms. Twin Res Hum Genet. 2007, 10: 604-625. 10.1375/twin.10.4.604.CrossRefPubMed
38.
Koldehoff M, Steckel NK, Hlinka M, Beelen DW, Elmaagacli AH: Quantitative analysis of chimerism after allogeneic stem cell transplantation by real-time polymerase chain reaction with single nucleotide polymorphisms, standard tandem repeats, and Y-chromosome-specific sequences. Am J Hematol. 2006, 81: 735-746. 10.1002/ajh.20693.CrossRefPubMed
39.
Taback B, Giuliano AE, Hansen NM, Singer FR, Shu S, Hoon DS: Detection of tumor-specific genetic alterations in bone marrow from early-stage breast cancer patients. Cancer Res. 2003, 63: 1884-1887.PubMed
40.
Iniesta P, Massa MJ, Gonzalez-Quevedo R, de Juan C, Moran A, Sanchez-Pernaute A, Cerdan J, Torres A, Balibrea JL, Benito M: Loss of heterozygosity at 3p23 is correlated with poor survival in patients with colorectal carcinoma. Cancer. 2000, 89: 1220-1227. 10.1002/1097-0142(20000915)89:6<1220::AID-CNCR5>3.0.CO;2-Z.CrossRefPubMed
41.
Wu CL, Sloan P, Read AP, Harris R, Thakker N: Deletion mapping on the short arm of chromosome 3 in squamous cell carcinoma of the oral cavity. Cancer Res. 1994, 54: 6484-6488.PubMed
42.
Rimessi P, Gualandi F, Morelli C, Trabanelli C, Wu Q, Possati L, Montesi M, Barrett JC, Barbanti-Brodano G: Transfer of human chromosome 3 to an ovarian carcinoma cell line identifies three regions on 3p involved in ovarian cancer. Oncogene. 1994, 9: 3467-3474.PubMed
43.
An HX, Niederacher D, Picard F, van Roeyen C, Bender HG, Beckmann MW: Frequent allele loss on 9p21-22 defines a smallest common region in the vicinity of the CDKN2 gene in sporadic breast cancer. Genes Chromosomes Cancer. 1996, 17: 14-20. 10.1002/(SICI)1098-2264(199609)17:1<14::AID-GCC3>3.0.CO;2-5.CrossRefPubMed
44.
Zhang QX, Ding Y, Le XP, Du P: Studies on microsatellite instability in p16 gene and expression of hMSH2 mRNA in human gastric cancer tissues. World J Gastroenterol. 2003, 9: 437-441.CrossRefPubMedPubMedCentral
45.
Silva JM, Gonzalez R, Provencio M, Dominguez G, Garcia JM, Gallego I, Palacios J, Espana P, Bonilla F: Loss of heterozygosity in BRCA1 and BRCA2 markers and high-grade malignancy in breast cancer. Breast Cancer Res Treat. 1999, 53: 9-17. 10.1023/A:1006082117266.CrossRefPubMed
46.
Niederacher D, Picard F, van Roeyen C, An HX, Bender HG, Beckmann MW: Patterns of allelic loss on chromosome 17 in sporadic breast carcinomas detected by fluorescent-labeled microsatellite analysis. Genes Chromosomes Cancer. 1997, 18: 181-192. 10.1002/(SICI)1098-2264(199703)18:3<181::AID-GCC5>3.0.CO;2-Y.CrossRefPubMed
Metadata
Title
A critical evaluation of loss of heterozygosity detected in tumor tissues, blood serum and bone marrow plasma from patients with breast cancer
Authors
Heidi Schwarzenbach
Volkmar Müller
Cord Beeger
Miriam Gottberg
Nicole Stahmann
Klaus Pantel
Publication date
01-10-2007
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 5/2007
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr1772

Other articles of this Issue 5/2007

Breast Cancer Research 5/2007 Go to the issue

Research article

BP1 transcriptionally activates bcl-2and inhibits TNFα-induced cell death in MCF7 breast cancer cells

Review

P-cadherin expression in breast cancer: a review

Research article

Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status

Research article

Recent changes in breast cancer incidence and risk factor prevalence in San Francisco Bay area and California women: 1988 to 2004

Research article

Comparison of different commercial kits for HER2 testing in breast cancer: looking for the accurate cutoff for amplification

Research article

Intrinsic genetic characteristics determine tumor-modifying capacity of fibroblasts: matrix metalloproteinase-3 5A/5A genotype enhances breast cancer cell invasion
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits